P3 Health Partners reaffirms FY2022 guidance and provides FY2023 outlook; 10-K filing delayed to March 30

P3 Health Partners Inc.

Reaffirmed FY2022 revenue $1.025B-$1.075B (61%-69% YoY growth) and >100k at-risk MA members.
FY2022 adjusted EBITDA loss reaffirmed at $118M-$128M; FY2023 adjusted EBITDA loss guided at $40M-$60M.
Preliminary 2023 revenue guidance $1.20B-$1.25B; at-risk MA membership 115k-120k.
Expects positive adjusted EBITDA in 2024; 10-K filing delay due to audit timing, not operational issues.
Earnings call scheduled for March 30, 2023 after market close.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.8

P3 Health Partners Inc. updated its fiscal year ended December 31, 2022 guidance (reaffirmed).

Period: fiscal year ended December 31, 2022
Guidance: reaffirmed
Result: preliminary results

Exact text from the filing

expects to report revenue of between $1.025 billion and $1.075 billion

View on SEC.gov

13 earnings releases filed in the last 30 days. Browse all earnings releases →

P3 Health Partners Inc. filing history →

Source: SEC EDGAR

accession 0001104659-23-032430

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.